Silexion Therapeutics Corp is making progress towards Phase 2/3 clinical trial initiation in the first half of 2026. New preclinical data shows SIL204’s efficacy against five KRAS-driven cancer types. The company raised over $9 million in the third quarter, strengthening its balance sheet. The financial results for the third quarter and nine months ended September 30, 2025, show decreased R&D and G&A expenses, with a net loss of $3.3 million and $7.5 million, respectively. As of September 30, 2025, Silexion had $9.2 million in cash and cash equivalents. The company is focused on advancing its lead product candidate for locally advanced pancreatic cancer.

Read more at GlobeNewswire: Silexion Therapeutics Reports Third Quarter 2025 Financial